Abstracts
schizoaffective, and delusional disorders, but also may appear in patients diag-
nosed with bipolar and personality disorders [6]. In order to improve adherence
to treatment, antipsychotics were formulated as long-acting injectables (LAIs).
LAIs have been widely studied in schizophrenia and evidence suggests that they
could be also used for the treatment of other mental disorders. Nonetheless, the
role of the newest LAIs in mental health has been scarcely studied.
Aims: to evaluate the use of the aripiprazole once monthly (A1M), paliperidone
1- and 3-month (PP1M, PP3M) against the treatment with oral antipsychotics
(OAP), using the following clinical Outcomes: (1) the number of hospital read-
missions in the last 5 years, (2) the number of hospital readmissions one year
later and (3) the use of concomitant OAP.
Methods: we designed a transversal study by using 196 patients admitted to the
Acute Psychiatry Unit of the Reina Sofia University Hospital (Murcia, Spain) from
2020–2021. All patients were treated with oral or LAI antipsychotics. We
collected data about 5-years previous admissions and the treatment up to present
admission. Furthermore, we followed the patients during 1 year to assess new
hospital admissions. All analyses were performed using IBM SPSS Statistics
version 21.0 (IBM Corp., Armonk, NY, USA). Variables associated in the uni-
variate analysis and variables with statistical trend (p < 0.1) were entered as
factors in a bivariate logistic regression model to identify the variables inde-
pendently associated with hospital admission. Student’s t-test was used to assess
differences in total antipsychotic treatment intake expressed as haloperidol
equivalents (mg/day) within groups. Differences with a p value <0.05 were
considered significant.
Results: bivariate logistic regression analysis showed that being treated with
OAP was significantly associated with higher risk of hospital admission in the last
5-years (p¼0.021; OR¼1.38, 95%IC¼1.17-1.87). Furthermore, Kaplan-Meier
curves showed that LAI treatment during 19.6 (3.17) months significantly
reduced 5-years hospital readmission. Nonetheless, no differences between
groups were observed 1 year after the last hospital admission. 61% of patients
were treated as antipsychotic monotherapy in the OAP while only 29% in the LAI
group. The most prescribed OAP was olanzapine. Student t-test failed to show
differences in total antipsychotic daily dose. Nonetheless, one-way ANOVA
showed statistical differences between LAIs groups. In particular, patients treated
with PP1M or PP3M were significantly (p¼<0.05, p<0.01) prescribed with
lower antipsychotic daily dose (mg/day: PP1M¼7.21.4, PP3M¼5.80.7)
compared with the patients treated with biweekly LAIs (20.32.8).
Conclusions: the treatment with LAIs was associated with a lower risk of hos-
pital admissions. PP1M and PP3M also lowered the total daily dose of antipsy-
chotic prescription. Further research is needed to truly establish the role of the
LAIs in mental health.
No conflict of interest
doi: https://doi.org/10.1016/j.nsa.2022.100296
P.0204
NEUROSCIENCE APPLIED 1 (2022) 100112 100297
Cardiometabolic risk in patients with first episode of schizophrenia
M. Jirka 1. 1 University Hospital Hradec Kralove, Department of Psychiatry, Hradec
Kr

alov
e, Czech Republic
Background: Schizophrenia is associated with 2- to 3-fold excess mortality and
10- to 30-year gap in life expectancy that has been widening compared with the
general population. The vast majority of this premature mortality is related to
cardiovascular and metabolic illnesses. Reasons for the excess cardiometabolic
risk are complex, involving schizophrenia-related factors, poverty, unhealthy
lifestyle, suboptimal medical monitoring and care, and adverse effects of treat-
ment. Assessment and screening for cardiometabolic risk factors is recommended
in schizophrenia treatment guidelines. Individuals with a first episode schizo-
phrenia are at an increased risk for cardiometabolic disorders due to elevated
clinical risk markers and unhealthy lifestyle. They are particularly susceptible to
rapid and pronounced weight gain within the first year of treatment. Unfortu-
nately, little is known about the trajectory of cardiometabolic risks during the
course of schizophrenia.
Methods: In the prospective study, we investigated the plasma levels of hsCRP
(high sensitivity C-reactive protein) and lipids and measured weight and BMI
(Body Mass Index) in a group of forty-nine drug-naïve patients (nineteen females)
with newly diagnosed schizophrenia (mean age 26.15.9, range 18-40 years).
The control group consisted of forty-seven healthy volunteers (twenty females)
(mean age 25.55.4, range 18-42). We evaluated the cardiometabolic parame-
ters at the time of admission to the hospital and after three and twelve months
97
NEUROSCIENCE APPLIED 1 (2022) 100112
during antipsychotic treatment.
Results: Weight (mean 67.7 vs. 72.5 kg; p¼0.104), BMI (mean 22.5 vs. 23.2;
p¼0.098), the hsCRP level (1.98 vs. 1.77 mg/l; p¼0.321), total cholesterol (4.3
vs. 4.11 mmol/l; p¼0.543), LDL (low-density lipoprotein) cholesterol (2.40 vs.
2.11 mmol/l; p¼0.191) and TAG (triglycerides) (0.91 vs. 0.97 mmol/l; p¼0.057)
did not differ between the groups. The glucose level (mean 5.49 vs. 4.36 mmol/l;
p<0.001), insulin (mean 5.50 vs. 1.67 mIU/l; p<0.001), HOMA-IR (Homeostatic
Model Assessment for Insulin Resistance) (mean 1.39 vs. 0.35; p<0.001), HDL
(high-density lipoprotein) cholesterol (mean 1.47 vs. 1.22 mmol/l; p<0.001) and
sP-selectin (soluble P-selectin) (mean 172.2 vs. 118.2 ng/ml; p<0.001) were
significantly increased in the study group compared to the controls. Some car-
diometabolic risk factors significantly increased within the first year of treat-
ment. The average weight gain was 9.37 kg (p<0.001), the increase in the hsCRP
level was 1.34 mg/l (p<0.005), in LDL 0.57 mmol/l (p<0.001), in TAG 0.41
mol/l (p<0.002) and in the atherogenity index 0.78 (p<0.001) after one year of
the treatment.
Conclusions: Cardiometabolic risk factors are already present early in schizo-
phrenia. Physical health monitoring and targeted lifestyle interventions,
including smoking cessation, and a treatment with cardiometabolic low-risk
antipsychotic agents are needed from the earliest phases of schizophrenia.
Further research is necessary to assess the trajectory of cardiometabolic risk,
underlying mechanisms and mediating variables, including the search for the
best treatment choices for patients with the first episode of schizophrenia.
Conflict of interest
Disclosure statement:
This study was supported by the Czech Ministry of Health MH CZ – DRO (UHHK,
00179906).
doi: https://doi.org/10.1016/j.nsa.2022.100297
P.0206
NEUROSCIENCE APPLIED 1 (2022) 100112 100298
The association between childhood maltreatment and social functioning
in psychotic disorders: a systematic review
N.E. Fares Otero 1,2, L.M. Neuhaus 2, S. Wiese 2, J.M. Estrada-Lorenzo 3,
I. Sch€afer 4, S. Trautmann 2. 1 Bipolar and Depressive Disorders Unit- Institute of
Neurosciences- University of Barcelona- Hospital Clínic Barcelona- CIBERSAM-
IDIBAPS, Department of Psychiatry and Psychology, Barcelona, Spain; 2 Medical
School Hamburg, Department of Psychology, Hamburg, Germany; 3 University
Hospital 12 de Octubre, Health Library, Madrid, Spain; 4 University Medical Centre
Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Hamburg,
Germany
Background: Psychotic disorders (PD) are among the leading causes of disability
worldwide1. Childhood maltreatment (CM) is associated with the onset and
course of PD2. CM is further related to neurobiological and clinical character-
istics3 that could be relevant for social functioning4, which range from inter-
personal relations and work skills to complex social cognitive processes and
behaviour. However, the extent to which CM and social functioning are associ-
ated in individuals with PD across different domains, is yet poorly understood.
Aims: To systematically review and synthesise available evidence on the rela-
tionship between CM and different domains of social functioning, and to sum-
marise evidence for potential moderators and mediators of these associations.
Methods: Articles peer reviewed and published in English, German and Spanish,
up to March 4, 2022, were identified in PubMed, PsycINFO, Embase, Web of
Science, Pilots, and manual searches, using multiple terms for “child abuse”,
“social functions” and “psychosis”. Eligible studies investigated an association
between CM and at least one social functioning domain in adults with PD.
Screening, data extraction, and risk of bias assessment were independently
conducted; discrepancies were resolved through consensus.
Results: From 5,218 identified records, a total of 51 studies were included,
comprising 13,052 individuals with PD. The included studies found: (i) Consis-
tent evidence for a relationship between CM and poor social relationships, less
engaging in leisure and work activities, and impaired face emotion recognition;
(ii) Mixed results in the relationship between CM and theory of mind perfor-
mance; (iii) A dose-response-relation between severity and number of CM ex-
periences and social functioning; (iv) Evidence supporting a moderating role of
type and timing of CM exposure, gender, and duration of illness in the association
between CM and social functioning; (v) Differences between early psychosis and
chronic schizophrenia with CM being related to reduced social networks and
socio-cultural interests in early psychosis and to poor social roles, behavioural